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The alternative pathway (AP) of complement is constantly active in plasma and
can easily be activated on self surfaces and trigger local inflammation. Host cells
are protected from AP attack by Factor H (FH), the main AP regulator in plasma.
Although complement is known to play a role in atherosclerosis, the mechanisms of its
contribution are not fully understood. Since FH via its domains 5–7 binds apoliporotein
E (apoE) and macrophages produce apoE we examined how FH could be involved
in the antiatherogenic effects of apoE. We used blood peripheral monocytes and
THP-1 monocyte/macrophage cells which were also loaded with acetylated low-density
lipoprotein (LDL) to form foam cells. Binding of FH and apoE on these cells was
analyzed by flow cytometry. High-density lipoprotein (HDL)-mediated cholesterol efflux
of activated THP-1 cells was measured and transcriptomes of THP-1 cells using mRNA
sequencing were determined. We found that binding of FH to human blood monocytes
and cholesterol-loaded THP-1 macrophages increased apoE binding to these cells.
Preincubation of fluorescent cholesterol labeled THP-1 macrophages in the presence of
FH increased cholesterol efflux and cholesterol-loaded macrophages displayed reduced
transcription of proinflammatory/proatherogenic factors and increased transcription of
anti-inflammatory/anti-atherogenic factors. Further incubation of THP-1 cells with serum
reduced C3b/iC3b deposition. Overall, our data indicate that apoE and FH interact with
monocytic cells in a concerted action and this interaction reduces complement activation
and inflammation in the atherosclerotic lesions. By this way FH may participate in
mediating the beneficial effects of apoE in suppressing atherosclerotic lesion progression.
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INTRODUCTION
Complement (C) system is part of the humoral innate immune
response. It quickly attacks microbes and foreign particles
invading the human body. Activation of complement through
any of the three pathways, the classical, alternative (AP), and
lectin pathways, leads to cleavage of C3 and covalent surface
deposition of the C3b fragment that is capable of forming an
enzyme with factor B. Surface deposited C3b and its fragments,
inactive C3b (iC3b) and C3dg, are important opsonins that can
be recognized by complement receptors expressed by phagocytes.
Further activation of the C cascade leads to formation of
membrane attack complexes and release of proinflammatory
chemotactic and anaphylatoxic protein fragments C3a and C5a
that mediate their effects by binding to receptors on phagocytes.
AP is constantly active in plasma leading to low grade
challenge to all plasma-exposed particles and surfaces by
spontaneous hydrolysis or enzymatic activation of C3. Activation
proceeds rapidly through amplification on surfaces that are
missing efficient regulatory mechanisms. Factor H (FH) is the
main AP regulator as it keeps this spontaneous activation in
control (1). This is obvious since depletion of plasma/serum from
FH or blockage of FH by autoantibodies leads to activation of the
AP leading to overconsumption and loss of active complement
within <30min (2, 3). FH is an elongated molecule composed of
20 domains. The N-terminal domains 1–4 are responsible for FH
regulatory activity while domains 19–20 on the C-terminal end
are responsible for the self surface recognition (4). Domain FH19
binds to surface-deposited C3b, while FH20 binds sialic acids and
glycosaminoglycans (GAGs) present on self surfaces (5). In this
way, FH discriminates host self surfaces from non-self ones. Also
domains 6–7 of FH are important for self surface recognition.
These mediate interaction with sulphated GAGs, heparin, and
C-reactive protein (6, 7). When bound to C3b, the cofactor
activity of FH helps in inactivation of C3b to iC3b by factor I
and simultaneous inhibition of factor B binding to C3b (8, 9).
Moreover, FH prevents further AP amplification by accelerating
the decay of formed AP convertases (10). AP activation does
not need a trigger as it is based on continuous low-grade
activity. However, imbalance between activation and regulation
e.g., when numerous C3b deposits are formed on protein
complexes can lead to enhanced AP activation in serum/plasma
(11). Recently, it has become clear that AP dysregulation is
a central event in development of several complement-related
diseases to which mutations or polymorphisms in domains
FH5-7 and FH19-20 predispose. While mutations in FH19-
20 cause atypical hemolytic uremic syndrome (aHUS), the
Y402H polymorphism in domain 7 is associated with age-related
macular degeneration (AMD) (12, 13) and dense deposit disease
(DDD) (14).
Atherosclerosis is a chronic multifactorial inflammatory
disease caused by the subendothelial accumulation of lipids,
immune cells and fibrous elements in arteries leading to
thickening and hardening of the arterial wall. Low-grade
inflammation is a key mediator of the disease. Both adaptive
and innate immune responses are crucial for initiation and
progression of atherosclerosis, and these mechanisms have been
exploited to develop new diagnostic biomarkers and therapies
for patients recently (15). The hallmark of early atherosclerotic
lesion is the formation of fatty streaks composed of cholesterol-
laden macrophages, which are formed when low density
lipoproteins (LDL) are modified by oxidation or proteolytic
modification and accumulated in the subendothelium of arteries
leading to monocyte recruitment and differentiation into
macrophages (16). The balance between proinflammatory M1
type macrophages and anti-inflammatory M2 type macrophages
plays a crucial role in the pathogenesis of atherosclerotic plaques.
The antiatherosclerotic activity of apoE is based on its ability
to regulate lipoprotein metabolism and to promote cholesterol
efflux from cells (17, 18). Endogenous production of apoE
by macrophages in blood vessel walls has been shown to
be critical in the prevention and healing of atherosclerotic
plaques. Importantly, apoE modulates macrophage polarization
into the anti-inflammatory M2 phenotype (17) and promotes
reverse cholesterol transport from peripheral cells to high density
lipoprotein (HDL) for further transportation of cholesterol to the
liver for excretion (19).
Genetic variations in the APOE gene coding for
apolipoprotein E constitute important risk factors both for
AMD and atherosclerosis. Interestingly, similar underlining
mechanisms including disturbances in lipid metabolism,
oxidative stress and the inflammatory process are closely
associated in the pathogenesis of both diseases. It has also been
shown that in human eyes with AMD, FH co-localizes with and
binds to oxidized lipids in drusen, fatty deposits under the retina.
It seems that the common FH variant 402Y has a higher affinity
for oxidized lipids than the risk allele 402H suggesting a stronger
FH-mediated complement inhibition of the effects of oxidized
lipids on macrophages (20).
We have shown before that FH binds both lipid-free and high
density lipoprotein (HDL) associated apoE via domains 5–7 and
thereby regulates AP activation in plasma (21). The present study
was set up to investigate whether FH and apoE interaction could
play a role in the induction and progression of atherosclerosis
by macrophages. We show here that FH increases apoE binding
to monocytes and THP-1 macrophages possibly via simultaneous
interaction between cell surface sialic acids and apoE and thereby
regulates local complement activation. Moreover, FH interaction
with THP-1 macrophages and cholesterol-labeled cells increases
macrophage-mediated cholesterol efflux and modulates the
expression of inflammatory genes suggesting a yet unexplored
anti-inflammatory mechanism for FH.
MATERIALS AND METHODS
Proteins
Cloning and Pichia pastoris expression of the recombinant
fragments FH5-7, FH19-20, and FH1-4 has been described
earlier (22, 23). If necessary, fragments were further purified
by passing through a HiLoad 16/60 Superdex 200 prep-grade
gel filtration column (GE healthcare) in phosphate buffered
saline (NaCl 300mM, KCl 5.4mM, Na2HPO4 20mM, KH2PO4
3.6mM, pH 7.4), and concentrated using heparin affinity
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chromatography. Labeling of proteins was performed using N-
hydroxysuccinimide-reactive Red dye (NT647, catalog no. L001)
following the manufacturer’s instructions (NanoTemper).
Expression of apoE Proteins
The preparation of vectors, expression of recombinant apoE2,
apoE3, and apoE4 in the Escherichia coli BL21-Gold (DE3)
bacterial system following induction by IPTG, and purification by
immobilized metal affinity chromatography has been described
elsewhere (24–26).
Isolation of HDL and LDL and Acetylation
of Human LDL
LDL (d = 1.019–1.050 g/mL) and HDL (d = 1.063–1.210
g/mL) were isolated from plasma of healthy volunteers obtained
from the Finnish Red Cross Blood Service by sequential
ultracentrifugation using KBr for density adjustment (27). LDL
was acetylated by repeated additions of acetic anhydride (28).
Briefly, LDL (10mg as LDL protein) in 1.5ml LDL buffer
(150mM NaCl, 1mM EDTA, pH 7.4) was mixed 1:1 (vol/vol)
with saturated sodium acetate and stirred in ice-water bath
for 10min. Next 30 µl acetic anhydride was added four times
with 10min stirring intervals. After the fourth addition of
acetic anhydride, the incubation was continued for 60min with
continuous stirring. Finally, the mixture was dialysed for 24 h at
4◦C against LDL buffer.
Isolation of Peripheral Blood Cells, Cell
Cloning, and Culturing
For peripheral blood cell isolation blood was drawn to tubes
containing hirudin (Roche Diagnostics, Mannheim, Germany)
from healthy human volunteers after informed written and
signed consent (Ethical Committee decision 406/13/03/00/2015,
Hospital district of Helsinki and Uusimaa). The blood samples
were diluted 1:1 (v/v) with PBS and centrifuged through
a gradient (Histopaque R© 1.119 and 1.077; Sigma-Aldrich)
at 320 x g for 20min at 22◦C. The PBMC layer was
collected, washed once with RPMI 1640 (Gibco R©) containing
0.05% (w/v) HSA (RPMI-HSA) and diluted with RPMI-HSA.
U937 human monocytic cells were obtained from the ATCC
(American Type Culture Collection), cultured in RPMI medium
supplemented with penicillin/streptomycin and 10% (v/v) FCS.
CR3 was stably expressed in U937 cells using a lentiviral
expression system as described (29). We cloned the CD11b
(NM_001145808.1) and CD18 (NM_000211.4) cDNA in the dual
promoter lentiviral vectors, RP137 (BIC-PGK-Zeo) and RP-139
(BIC-PGK-Puro), respectively. These vectors were constructed
by replacing the Zeo-T2a-mAmetrine cassette from the BIC-
PGK-Zeo-T2a-mAmetrine (RP172) vector (30) with either a
Zeocin or Puromycin resistance gene. First CD11b was stably
expressed in U937 cells, subsequently these cells were used for
stable expression of CD18. THP-1 monocytes were transformed
to macrophages by incubating the cells for 48–72 h in the
presence of 100 nM phorbol 12-myristate 13-acetate (PMA) and
for generating cholesterol loaded cells mimicking foam cells
the macrophages were further incubated in the presence of
100µg/ml (as LDL protein) acetylated LDL for 24–48 h in serum
free media.
Detection of CR3 and Sialic Acid
Expression on Cells and Binding of FH on
Cell Surface Sialic Acids
The expression of CR3 was analyzed by incubating the cells in 50
µl RPMI-HSA at 5 × 106 cells/ml concentration for 45min with
FITC-conjugated anti-CD11b (sigma). The cells were washed
once with RPMI-HSA and expression of CR3 was detected by
flow cytometry. To detect the specificity of sialic acid expression
on different cells and FH binding to cell surface sialic acids the
cells were preincubated with 100U α2-3,6,8 Neuraminidase (New
England biolabs) or PBS for 30min at 37◦C. Next, 45 nM NT647
labeled Maackia Amurensis Lectin II (MAL II∗) or 200 nM
NT647-FH was added to the wells and the plate was further
incubated for 30min at 37◦C. The cells were washed once with
200 µl of icecold RPMI-HSA, centrifuged at 300 × g for 10min,
fixed with 100µl of 1% (v/v) paraformaldehyde (Thermo) RPMI-
HSA. Next, 2,000–10,000 cells were run by BD LSR Fortessa
flow cytometer (Lazer 640 nm, filter 670/30) and analyzed using
FlowJo V10 software, where the gating of the cells was performed
by using forward scatter (FSC) and side scatter (SSC) to find
viable, single cell events. Mean fluorescence intensities were
calculated for the gated cells.
ApoE, FH5-7 and Factor H Binding to Cells
Binding of FH or FH5-7 to peripheral blood monocytic cells,
U937 and THP-1 cells was studied by incubating 2 × 105 cells
with 200 nM of NT647-FH or 1,3µM of NT647 FH5-7 for
45min at 4◦C in round bottom 96-well plates. For inhibition
assays, cells were incubated for 30min at 4◦C with 1.5µM of
apoE, FH1-4 or 9 and 3µM of FH5-7 prior adding the labeled
protein. The cells were washed once with 200µl of icecold RPMI-
HSA, centrifuged at 300 × g for 10min and fixed with 100 µl
of 1% (v/v) paraformaldehyde RPMI-HSA. To study the effect
of apoE-FH interaction and their binding to monocytic cells a
dilution series of FH (Complement technologies), FH19-20 or
apoE was incubated in dark for 5min at 37◦C with a constant
200 nM concentration of NT647-labeled apoE or NT647-labeled
FH. Then 40 µl of hirudin blood isolated monocytes were added
in each well and incubated in dark for 25min at 37◦C. The
incubation was stopped by adding 300 µl of ice-cold PBS to the
tubes and the cells were run by flow cytometry and analyzed using
the gating strategy described earlier.
FH5-7 Binding to a Panel of Leukocyte
Receptors
Monocytes isolated from peripheral blood (PBMCs) cells (5
× 106 cells/ml) in RPMI-HSA 0.05% (w/v) were incubated in
the presence of 14µg/ml of FH5-7, or PBS for 15min on ice
followed by incubation with a panel of receptor specific FITC-,
PE- or APC-labeled antibodies using a 96-well U-plate (greiner,
Bio one) for 45min at 4◦C. The cells were washed with 200
µl of RPMI/HSA 0.05% (w/v) and fixed with 150 µl of 1%
(v/v) paraformaldehyde in RPMI-HSA 0.05% for 30min at 4◦C
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before counting the fluorescence of 10,000 cells using on FACS
flow cytometer (Lazers 405, 488, and 640 nm; filters 450/50,
525/50, and 670/30) and analyzed using the gating strategy
described earlier. The inhibition value of FH5-7 on receptor
specific antibody binding was calculated by dividing the mean
fluorescence of FH5-7 treated cells by PBS treated cells.
C3b/iC3b Deposition on FH Incubated
THP-1 Cells
Untreated THP-1 monocytes, PMA activated THP-1
macrophages, and PMA activated THP-1 macrophages loaded
with cholesterol by using acLDL (100/ml µg of LDL protein)
were incubated in the presence or absence of FH (320 nM)
for 24 h in 24-well tissue culture plates at 37◦C in 5% CO2
in serum free THP-1 medium using 4 x 105 cells/well/200 µl.
A 10 µl sample from the supernatant was taken at 0, 5 and
24 h timepoints after the media was centrifuged for 10min at
300 x g to remove any cellular debris. These culture media
aliquots were stored at −20 ◦C before analysis for the apoE
ELISA method. After 24 h the cells were detached using 200 µl
Cellstripper (Corning) for 45min at 37◦C, 5% CO2, harvested by
centrifugation as before and diluted with RPMI-HSA. Cells from
this assay were used to analyze NT647-FH binding (described
earlier), mRNA expression, apoE secretion (described later),
ABCA1 protein expression and complement activation assays.
To detect ABCA1 protein expression the cells were incubated
with 0.3 µg/4 x 105 cells/well/150 µl mouse anti-ABCA1
antibody (abcam) washed once by centrifugation and incubated
with 1:200 dilution of Alexa Fluor 488 conjugated goat anti-
mouse IgG (Invitrogen). To compare serum complement activity
in the presence or absence of preincubated FH 5 x 104 of THP-1
cells were incubated for 15min in a 50 µl volume of 20% (v/v)
serum. Cells were washed once by centrifugation and incubated
with 2 µl of FITC conjugated anti-C3b (Cederlane) for 45min at
4◦C. The cells were washed, fixed, run by flow cytometry (Lazer
488, filter 525/50) and analyzed as described earlier.
Effect of FH on apoE Secretion and Binding
to THP-1 Cells
The cells detached from the tissue culture 24-well plates were
incubated in the presence of 2 µl of rabbit anti-human apoE
(600µg/ml, non affinity purified) in a 50 µl volume of RPMI-
HSA 0.05% (w/v) for 45min at 4◦C. The cells were washed once
by centrifugation and incubated in the presence of 1:100 diluted
488 goat anti-rabbit antibody (Life technologies) for 45min at
4◦C. After incubation the cells were washed, fixed and analyzed
by flow cytometry as described earlier (Lazer 488, filter 525/50).
Secretion of apoE by THP-1 cells was analyzed from 8 µl of
culture media collected at different time points using apoE ELISA
protocol as previously described (31).
Cholesterol Efflux Assay
The cholesterol efflux assay was performed according to
manufacturer’s instructions (Abcam) using THP-1 cells activated
for 24 h with PMA. The cells were labeled overnight with
fluorescently-labeled cholesterol in the presence or absence of
650 nM FH. After overnight labeling the PMA activated and
cholesterol labeled THP-1 macrophages were washed gently
with 200 µL of RPMI media and incubated then in the
presence of 50 µg of HDL (as HDL protein) as cholesterol
acceptor. After 5 h incubation the media and supernatant of
lysed cells were measured separately for fluorescence (Ex/Em
= 482/515 nm). The ratio between fluorescence intensity of
media and fluorescence intensity of cell lysate plus media were
calculated as percentage of cholesterol efflux.
RNA-Sequencing
RNA sequencing method was designed based on the Drop-seq
protocol described earlier (32). Briefly, the cells were mixed with
lysis buffer (0.3% (v/v) triton, 20mM DTT, 2mM dNTPs) in
wells of U-bottomed 96-well plate. Magnetic Dynabeads (M-
270 Streptavidin, Thermo Fisher Scientific) coated with Indexing
Oligonucleotides (Integrated DNA Technologies, Table 1) were
added to each well. After 5min of incubation at ambient
temperature the magnetic beads were separated from the
supernatant and washed twice with 6X SSC buffer. Subsequently,
the beads were combined with RT mix, containing 1 x Maxima
RT buffer, 1mM dNTPs, 10 U/µl Maxima H- RTase (all
ThermoFisher Scientific), 1 U/µl RNase inhibitor (Lucigen), and
2.5µM Template Switch Oligo (Integrated DNA Technologies).
Samples were incubated in a T100 thermal cycler (BioRad) for
30min at 22◦C and 90min at 52◦C. The beads were washed
twice with 6X SSC buffer and once in PCR-grade water. The
constructed cDNA was amplified by PCR in a volume of
15 µl using 5 µl of RT mix as template, 1x HiFi HotStart
Readymix (Kapa Biosystems) and 0.8µM SMART PCR primer.
The samples were thermocycled in a T100 thermocycler (BioRad)
as follows: 95◦C 3min; subsequently four cycles of: 98◦C for
20 s, 65◦C for 45 s, 72◦C for 3min; following 13 cycles of:
98◦C for 20 s, 67◦C for 20 s, 72◦C for 3min; and with the final
extension step of 5min at 72◦C. The PCR products were pooled
together and purified with 0.6X Agencourt AMPure XP Beads
(Beckman Coulter) according to the manufacturer’s instructions.
They were eluted in 10 µl of molecular grade water. The 3
′
-
end cDNA fragments for sequencing were prepared using the
Nextera XT (Illumina) tagmentation reaction with 600 pg of the
PCR product serving as an input. The reaction was performed
according to manufacturer’s instruction, with the exception of
the P5 SMART primer that was used instead of S5xx Nextera
primer. Subsequently, the samples were PCR amplified as follows:
95◦C for 30 s; 11 cycles of 95◦C for 10 s, 55◦C for 30 s, 72◦C for
30 s; with the final extension step of 5min at 72◦C. Samples were
purified twice using 0.6X and 1.0X Agencourt AMPure Beads
(Beckman Coulter) and eluted in 10 µl of molecular grade water.
The concentration of the libraries was measured using a Qubit
2 fluorometer (Invitrogen) and the Qubit DNA HS Assay Kit
(ThermoFisher Scientific). The quality of the sequencing libraries
was assessed using the LabChip GXII Touch HT electropheresis
system (PerkinElmer), with the DNA High Sensitivity Assay
(PerkinElmer) and the DNA 5K/RNA/Charge Variant Assay
LabChip (PerkinElmer). Samples were stored at −20◦C. The
libraries were sequenced on Illumina NextSeq500, with a custom
primer (Table 1) producing read 1 of 20 bp and read 2 (paired
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SMART PCR primer AAGCAGTGGTATCAACGCAGAGT
P5 SMART primer AATGATACGGCGACCACCGAGATCTACACGCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGT*A*C
Sequencing read 1 GCCTGTCCGCGGAAGCAGTGGTATCAACGCAGAGTAC
* = phosphorothioate bond added
end) of 55 bp (32). Sequencing was performed at the Functional
Genomics Unit of the University of Helsinki, Finland.
Read Alignment and Generation of Digital
Expression Data
Raw sequence data was filtered to remove reads shorter than
20 bp. Subsequently, the original pipeline suggested in Macosko
et al. (32) for processing of drop-seq data was used. Briefly,
reads were additionally filtered to remove polyA tails of length
6 or greater, then aligned to the human (GRCh38) genome
using STAR aligner (33) with default settings. Uniquely mapped
reads were grouped according to the 1–12 barcode, and gene
transcripts were counted by their Unique Molecular Identifiers
(UMIs) to reduce the bias emerging from the PCR amplification.
Digital expression matrices (DGE) reported the number of
transcripts per gene in a given sample (according to the distinct
UMI sequences counted).
Statistical Methods
Statistical analyses between multiple samples were performed
using one-way ANOVA supplemented with non-parametric
Tamhane’s multiple-comparison test. Statistical differences
between two independent samples were calculated using
non-parametric Mann-Whitney U-test (SPSS for Windows,
Analytical Software).
RESULTS
Factor H Binds to Monocytic Cell CR3 via
CD11b
FH interacts with human cell surfaces mainly via C3b and
cell surface glycosaminoglycans, like heparan sulfate, and sialic
acids. Previous studies have shown that especially on endothelial
cells and platelets the presence of sialic acids is crucial for
efficient FH-mediated complement regulation (34). In addition
to surface sialic acids, FH has been shown to interact with CR3
(CD11b/CD18) on human neutrophils in the absence of C3b
deposits (35). We studied binding of FH to different ligands
on monocytes and monocytic cell lines to find out how these
interactions could be altered by apoE that is known to be secreted
bymacrophages and to interact with FH domains 5–7 (21, 36). By
using NT647-labeled FH we could detect clear binding of FH to
monocytes even in the absence of C3b, while binding of FH to
lymphocytes was closer to the background values (Figure 1A).
To find out the receptor that interacts with the apoE binding
domains FH5-7 (location of the apoE binding domains is shown
in Figure 1B) on monocytes we performed a screening assay
where the cells were preincubated with the recombinant FH5-7
fragment prior to adding the anti-receptor antibody. Incubation
of the cells with FH5-7 resulted in a clear reduction in anti-
CD11b binding that is the alpha-chain of the integrin-type
CR3 receptor heterodimer (CD11b/18; Figure 1C). In addition,
similar inhibition was also detected with antibodies against CD35
and CD89. Binding of FH5-7 on CR3 was further analyzed
using CR3 overexpressing U937 monocytic cells (Figure 1D).
Binding of NT647-labeled FH5-7 on these cells was reduced in
the presence of increasing concentrations of non-labeled FH5-7
(3 and 9µM) and on empty U937 cells that do not express CR3.
Binding of apoE to Monocytes Is Increased
by Factor H
To study further the interaction between the apoE binding ligand
FH and CR3 on human monocytes, we next performed an
assay to see whether apoE could alter FH-CR3 interaction on
U937 monocytic cells overexpressing the receptor. We found
that on CR3 overexpressing U937 cells binding of NT647-FH
was clearly inhibited by apoE2 to the level of binding of FH
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FIGURE 1 | Factor H binding to peripheral blood leukocytes. (A) Peripheral blood mononuclear cells were incubated with NT647-labeled FH and the mean
fluorescence intensities were analyzed by flow cytometry (n = 3). (B) Schematic structure of the full length FH and the location of domains 5–7 that interact with apoE.
The binding sites of different ligands, apoE, pentraxin3 (PTX3), monomeric C-reactive protein (mCRP) and heparin sulfate, and the common polymorphic Y402H site
on domain 7 are shown. (C) Screening of FH5-7 binding by a panel of antibodies directed against various receptors and surface molecules on monocytes. Peripheral
blood monocytic cells were preincubated for 30min with or without 12µg/ml of FH5-7 prior adding 2 × 105 cells cells/well in a 96-well plate with FITC-, APC- and/or
PE-labeled antibody. Mean fluorescence intensities were calculated from the gated cells using flow cytometry. Inhibition of antibody binding was calculated by dividing
the mean fluorescence of FH5-7 treated cells by PBS treated cells (FH5-7 vs. control). The CD11b part of CR3 dimer is marked. The dashed line shows the level of
anti-CD11b binding in the presence of FH5-7 (< 0.8) compared to binding of the antibody without FH5-7 (1.0). (D) CR3 expressing and empty U937 mononuclear
cells were incubated with NT647 labeled FH5-7 in the presence or absence of unlabeled FH5-7 (x-axis). Statistical significance between multiple samples was
calculated using one-way ANOVA supplemented with non-parametric Tamhane’s post-hoc multiple comparison test. Error bars indicate SD. * = p < 0.05.
to cells devoid of CR3. A slight inhibition was also detected by
apoE3 and apoE4 but the levels of inhibition were not statistically
significant (Figure 2A). As the apoE2 isotype showed significant
inhibition we used the apoE2 isoform in the further assays.
Surprisingly, when the same inhibition assay was performed
using peripheral blood monocytes and lymphocytes we did not
detect any inhibition of NT647-FH binding in the presence
of increasing concentrations of unlabeled apoE (Figure 2B).
On the contrary, a clear increase in binding of NT647-apoE
was detected when the cells were incubated with increasing
concentrations of unlabeled FH, while FH19-20 did not have
the same effect. This indicates that FH increases rather than
attenuates apoE binding to monocytes. To further study the cell
surface receptors leading to increased binding of apoE to these
cells, and because both apoE and FH are known to interact
with cell surface heparan sulfate, we incubated monocytes with
NT647-apoE and FH and increasing concentrations of anti-
heparin antibody. Here, binding of NT647-apoE in the presence
of anti-heparin antibody was reduced to the level of NT647-
apoE only (Figure 2C) suggesting that increased binding of apoE
to these cells is dependent on FH and cell surface heparan
sulfate.
Because we could detect inhibition of FH binding by apoE
only to U937 cells overexpressing CR3 but not to monocytes
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FIGURE 2 | Inhibition of Factor H/apoE binding to U937 and peripheral blood cells. (A) Binding of NT647-FH on U937 cells expressing CR3 in the absence (Buffer)
or presence of 1.5µM of apoE2, 3 and 4 (n = 3). Control cells without CR3 (empty cells) shows binding of FH without the receptor. Binding of NT647-FH in the
presence of equal molarity of FH1-4 is shown. (B) Binding of NT647 labeled FH or apoE2 on peripheral blood cells with different concentrations of unlabeled inhibitor
(FH or apoE). Levels are calculated as relative to apoE binding at 73 nM FH concentration (n = 4). (C) Inhibition of apoE+FH binding to monocytes in the presence of
increasing concentrations of anti-heparin antibody. Anti-TREM-2 antibody was used as a negative control. Control (Neg. Cntrl. NT647-apoE) shows binding of apoE
on the cells without FH incubation and Control (Pos. Cntrl. NT647-apoE+FH) binding of apoE in the presence of FH and apoE only (n = 3). Statistical significance was
calculated using one-way ANOVA supplemented with non-parametric Tamhane’s post-hoc multiple comparison test. Error bars indicate SD. Percentages of mean
fluorescence intensities are shown as relative to the maximum intensity in each individual experiment. *= p < 0.05.
we hypothesized that on monocytes, where CR3 expression is
lower, FH could simultaneously bind to apoE and cell surface
sialic acids. This is because FH sialic acid binding domains are
located within domains FH19-20 and not on apoE interacting
domains FH5-7. This could also explain why apoE binding
was increased by FH to monocytes. As expected, the human
peripheral blood monocytes showed high sialic acid expression
and low CR3 expression while the U937 cells showed very
low expression of sialic acids and very high CR3 expression
(Figures 3A–C). The high expression levels of CR3 and low levels
of sialic acids on U937 cells may explain why inhibition of FH
binding to CR3 in the presence of apoE could only be detected
on these cells. To study the effect of sialic acids on binding of
FH different cell types were preincubated with neuraminidase
that removes cell surface sialic acids. All tested cells bound FH at
different levels, but only monocytes showed significant reduction
in FH binding after neuraminidase treatment. No decrease in
FH binding was detected on other tested cell types with lower
sialic acid expression (Figures 3D,E). These data suggest that FH
interacts with several different ligands on cells but binding of
FH to sialic acids via domains FH19-20 enables simultaneous
binding of apoE via domains FH5-7 and cell surface heparan
sulfate.
Binding of FH to THP-1 Cells Reduces
Complement Activation
Since we found that FH interacts directly with human
peripheral blood cells and because activation of complement
is known to play a role in the induction and progression of
atherosclerosis (37) we next studied whether FH binding to
macrophages and cholesterol-loaded macrophages could have
effect on local complement activation. To study this, we used
THP-1 monocytes stimulated with PMA and acetyl LDL as
model cells of early stage atherosclerosis. To avoid measuring
FH binding to damaged cells the viability was determined
using Trypan blue staining. These cell populations had cell
viability of approximately 70%. When THP-1 monocytes, THP-
1 macrophages and acLDL (i.e., cholesterol) loaded THP-
1 macrophages were studied for NT647-FH binding in the
absence of serum, a significant increase in FH binding was
detected on activated cholesterol loaded THP-1 macrophages
compared to THP-1 monocytes (Figure 4A). When the cells
were incubated with NT647-FH in the presence of 20% serum a
similar trend in FH binding could be detected indicating that the
increase in FH binding due to THP-1 activation is independent
from surface C3b deposition. Both THP-1 macrophages and
cholesterol loaded macrophages showed a significant increase
in FH binding compared to THP-1 monocytes (Figures 4A,B).
To study whether increased FH binding to these cells has
functional significance in reducing local complement activation,
the serum incubated cells were also analyzed for C3b deposition.
Surprisingly, preincubation of THP-1 cells in the presence of
FH showed a clear reduction in cell surface C3b deposition
only in the case of THP-1 macrophages (Figure 4C). Incubation
of THP-1 monocytes or cholesterol-loaded THP-1 cells in
20% serum did not lead to an increase in cell surface C3b
deposition. Therefore, the presence of additional FH had an
effect on the cell targeted complement activity only on THP-1
macrophages.
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FIGURE 3 | CR3 and sialic acid expression and FH binding to neuraminidase treated cells. (A) The expression of CR3 in different cell types was tested using
fluorescent labeled anti-CD11b antibody and flow cytometric analysis (n = 4). (B) Histogram showing distribution of CR3 receptors in different cell types. (C) Binding
of NT647 labeled Maackia amurensis lectin I (MAL II) to cell surface sialic acids in the presence or absence of 100U neuraminidase (n = 3). (D) Binding of NT647
labeled FH on cell surface sialic acids in the presence or absence of 100U neuraminidase (n = 3). (E) Binding of NT647 labeled FH on monocyte surface sialic acids in
the presence or absence of 100U neuraminidase presented in a histogram. Percentages of mean fluorescence intensities is shown as relative to the intensity of
neuraminidase treated U937 cells in each individual experiment. Histogram showing binding of NT647-FH on different cell types. Statistical significance between
multiple samples was calculated using one-way ANOVA supplemented with Tamhane’s post-hoc multiple comparison test. Statistical significance between two
samples was calculated using Mann-Whiney U-test. Error bars indicate SD. * = p < 0.05.
FH Increases apoE Binding to THP-1 Cells
and Macrophage-Mediated Cholesterol
Efflux
We used anti-apoE antibody to detect surface bound apoE on
THP-1 cells incubated with or without FH under cell culture
conditions. Similarly to the human peripheral monocytes apoE
binding was detected to activated THP-1 cells from which
cholesterol loaded THP-1 macrophages demonstrated significant
increase in apoE binding in the presence of FH, while binding
of apoE on THP-1 monocytes was low (Figure 5A). This
correlated well with the previous results, where cholesterol
loading of the cells resulted in most significant FH binding.
This indicates that FH binding to THP-1 cell surfaces increases
apoE binding as well. Because endogenous production of apoE
by macrophages in blood vessel wall has been suggested to
promote healing of atherosclerotic plaques and efficient transport
of cholesterol out from the cell (17), we analyzed the amount
of secreted apoE in the culture media. After a 24 h incubation
apoE secretion increased significantly from activated THP-
1 cells among which cholesterol-loaded THP-1 cells showed
highest apoE concentrations in the culture media (Figure 5B).
These results also correlated well with the transcriptome data
obtained from the apoE mRNA sequencing performed from the
isolated cells after 24 h incubation (Figure 5C). No difference
between cells incubated either in the presence or absence of
FH could be observed in apoE expression. ApoE is a good
cholesterol acceptor among many other apolipoproteins having
the potential to bind phospholipids ensuring cholesterol removal
(38). Therefore, we next studied whether elevated apoE binding
via FH to THP-1 cells could affect cholesterol efflux. Here, a
significant increase in cholesterol efflux could be detected from
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FIGURE 4 | Binding of FH and C3b deposition on THP-1 cells. Binding of NT647-labeled FH to THP-1 monocytes, THP-1 macrophages and cholesterol-loaded
THP-1 macrophages (foam cells) in the (A) absence (n = 3) or (B) presence (n = 3) of 20% serum. (C) Deposition of serum C3b on THP-1 monocytes, THP-1
macrophages and THP-1 foam cells in the presence or absence of FH (n = 3). Statistical significance was calculated using using one-way ANOVA supplemented with
Tamhane’s post-hoc multiple comparison test. Error bars indicate SD. Percentages of mean fluorescence intensities are shown as relative to the maximum intensity in
each individual experiment.
cholesterol-labeled THP-1 macrophages that were incubated in
the presence of FH when compared to cells in the absence of FH
(Figure 5D).
FH Increases Transcription of
Anti-inflammatory Genes in Macrophages
While cholesterol loaded THP-1 macrophages showed highest
apoE secretion FH did not have any effect on this. We,
however, hypothesized that FH could display anti-inflammatory
effects on macrophages as it interacts with both macrophages
and cholesterol loaded cells, inhibits complement activity
on macrophages, increases cholesterol efflux from cholesterol
labeled THP-1 macrophages and increases apoE interaction
with these cells as well. After 24 h incubation the THP-1
cell mRNAs were isolated and subjected to sequencing-based
transcriptome analysis covering over 27,000 RNA sequences
of different genes. Transcriptome analysis resulted in a
selection of transcripts that are associated with inflammation,
atherosclerosis and the complement system [Table 2, (18, 39–
46)]. When these transcriptomes were compared between the
FH and PBS incubated cells some clear effects/differences
could be seen between THP-1 macrophages and cholesterol
loaded THP-1 macrophages. As expected and based on
the above FH and apoE binding assays THP-1 monocytes
remained unresponsive to FH treatment. FH treatment resulted
in increase of ABCA1 transcription in cholesterol loaded
macrophages (foam cells) and in a significant increase in
transcription of a regulator of ABCA1 expression, PPAR-
α (40). Similarly, FH increased ABCA1 expression as well
and correlated with the significantly increased transcription
levels of the protein (Figure 5E). In THP-1 macrophages the
expression of proinflammatory factors CX3CR1, CCL5, and
SAAL1 was significantly decreased by FH. Moreover, a reduction
in transcription of complement receptor C5aR2 by FH in
macrophages was detected although this was not statistically
significant (p= 0.053).
DISCUSSION
In the present study we showed that complement FH
increases apoE binding to macrophages and leads to an
increased cholesterol efflux and reduced inflammation. The
FH/apoE interaction is hypothesized to limit the progression
of atherosclerosis as complement regulation by FH is
critical in the prevention self-cell damage and exacerbated
inflammation.
We previously found that FH interacts with apoE and reduces
complement activation in plasmaHDL particles (21). The current
study shows that this interaction apparently limits inflammation
in the atherosclerotic lesions by affecting macrophage activation
and cholesterol efflux. FH was found to interact with cell surface
sialic acids and CR3 on monocytic cells in the absence of
surface deposited C3b. In the presence of apoE the interaction
between FH and CR3 was inhibited, while apoE had no effect
on cells abundantly expressing sialic acids. In addition to CR3,
our screening assay suggested that domains 5–7 of FH could
also interact with CD35 (C3b/C4b receptor, CR1) and CD89.
From these, CR3 and CR1 are receptors directly involved in C-
mediated clearance and suppression of inflammation. We have
previously shown that FH blocks binding of CR1 to C3b (47) as
both molecules compete for the same binding site on C3b. Like
FH, CR1 is also a C regulator and therefore should be separately
analyzed for its role in C regulation during the atherosclerotic
lesion development. CR1 is mostly present on cell surfaces
but may also occur in soluble form. Its main function is the
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FIGURE 5 | Binding, secretion, and expression of apoE and cholesterol efflux by THP-1 cells. (A) Surface expression of and/or binding of apoE from culture
supernatants to THP-1 monocytes, THP-1 macrophages and cholesterol-loaded THP-1 cells detected by anti-apoE antibody. Cells were incubated with and without
FH for 24 h. Next, the cells were washed and detached from the tissue culture plates. Presence of apoE on cell surfaces were detected using anti-human apoE and
Alexa 488 labeled goat anti-rabbit antibody in flow cytometry. ApoE binding is shown as relative to the maximum intensity in each individual experiment (n = 3).
(B) Secretion of apoE to cell culture media by THP-1 monocytes, THP-1 macrophages and cholesterol-loaded THP-1 cells detected by ELISA (n = 4). (C) Number of
apoE mRNA transcripts analyzed by sequencing the cell isolated mRNA (n = 4) (D) Cholesterol efflux from non-loaded THP-1 macrophages labeled with fluorescent
cholesterol in the presence or absence of FH (n = 3). Cholesterol efflux in the presence of equal molarity of FH19-20 is shown. The positive (Pos. cntrl. from Abcam)
and non HDL treated controls (Neg. cntrl.) were included in the assay. (E) Protein expression and transcription levels of ABCA1 in THP-1 monocytes, THP-1
macrophages and cholesterol-loaded THP-1 cells detected by anti-ABCA1 antibody and mRNA sequencing. Levels are calculated as relative to the protein
expression and transcription in THP-1 macrophages (n = 4). Statistical significance calculated using Mann-Whiney U-test or one-way ANOVA supplemented with
Tamhane’s multiple comparison test. Error bars indicate SD.
transport of immune complexes and other unwanted materials
for clearance by macrophages in the spleen and liver.
Factor H binding to cell surface C3b increases in the presence
of self cell glycosaminoglycans and sialic acids. The binding of
FH to CR3 has still been regarded as controversial, probably
because of the possibility of C3b contamination in the sample.
The novelty we show here in the regard of FH and CD11b
interaction is that in the absence of C3b FH binding to CR3
expressing cells can be inhibited by apoE2 indicating a common
binding site between apoE and CR3 on FH domains 5–7.
Inhibition of FH binding to these cells by apoE3 and apoE4
was not that obvious indicating that the single amino acid
differences (Cys and Arg in positions 112 and 158) between the
apoE isotypes could alter binding to FH. Analogous differences
between these isoforms have been observed earlier due to their
structural variation. For instance, apoE3 and apoE4 protein
isoforms bind well to LDL-receptors, whereas apoE2 displays
defective binding (48). CR3 is known to interact with several
ligands. A major ligand that promotes phagocytosis is iC3b on
opsonised microbes and other particles. According to the mRNA
expression data obtained from FH stimulated cells it is unlikely
that FH could trigger CR3-mediated signaling, although a weak
but not significant increase in CLEC7A (dectin-1) expression
in cholesterol-loaded THP-1 macrophages could be detected in
the presence of FH (Table 2). This C-type lectin is upregulated
in anti-inflammatory M2 macrophages (49). However, earlier
studies have shown that binding of FH on CD11b suppresses
acute subretinal inflammation in mice indicating that FH-CR3
interaction could reduce inflammation in humans as well (50).
In contrast to the lacking inhibitory effect of apoE on FH-
monocyte interaction, the presence of FH increased apoE binding
to these cells significantly. This observation could be due to the
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Function Gene* THP-1 Foam cells THP-1 MQ THP-1 Mono
FH PBS p-value FH PBS p-value FH PBS p-value
Anti-
inflammatory
+ Nrf2 has a role in
resistance to oxidant stress.
Effect on atherogenesis may
vary depending on the
activator (39, 40)
NFE2L2 176.8 76.9 0.013 131.9 171.3 0.386 142.1 171.7 0.556




ABCA1 832.8 555.1 0.075 598.9 742.6 0.270 340.4 324.7 0.835
Antiatherogenic + PPAR-α and PPAR-γ
activators induce the
expression ABCA1 (42)
PPARA 18.3 3.5 0.032 11.6 26.1 0.211 16.4 18.1 0.925
Clearance + The protein levels of
RIPK1/3 are positively
correlated with the extent of
necroptosis (43)
RIPK1 39.8 3.5 0.004 20.3 43.7 0.053 25.4 9.2 0.071




SLC17A9 113.8 58.6 0.039 58.5 122.7 0.033 187.2 131.7 0.242
Proinflammatory – CX3CL1 is a chemokine
involved in the adhesion and
migration of leukocytes.
CX3CR1 0.0 3.5 0.356 0.0 13.0 0.001 6.8 12.4 0.633
Proinflammatory – CCL5 promotes
macrophage recruitment
and survival in human
adipose tissue (45)
CCL5 32.9 32.7 0.990 5.3 27.8 0.005 31.1 10.1 0.145
Proinflammatory – promotes proliferation of
fibroblasts upon
inflammation (46)
SAAL1 8.8 0.0 0.027 1.9 16.4 0.006 3.8 2.0 0.618
Proinflammatory + receptor for IL-3 IL-5
GMCSF
CSF2RB 29.4 0.0 0.000 22.2 14.8 0.614 17.4 22.1 0.789
Proinflammatory ∼ Binds C5a, involved in
coronary artery disease and
in pathogenesis of sepsis
(18)
C5AR2 400.1 267.2 0.114 438.1 612.9 0.053 115.0 132.5 0.684
No effect Binds C5a C5AR1 193.3 215.6 0.564 158.9 142.5 0.779 47.1 24.2 0.273
No effect apolipoprotein E APOE 669.2 611.6 0.828 375.9 278.4 0.415 90.8 74.6 0.684
No effect factor H CFH 0.0 0.0 0.0 5.1 0.214 0.0 0.0
*Panel of genes known to play a role in inflammation or atherosclerosis with the description of their function in inflammation. The numbers show the amount of mRNA transcripts (=mRNA
expression level). **Up- and downregulation marked as + and – and filled with dark or light gray colors, respectively. Statistical significance (p-values < 0.05 marked in bold numbers)
calculated between cells incubated with or without FH using Student’s t-test. Gray numbers = no statistical significance between FH and PBS treated cells.
high abundance of sialic acids and low expression levels of CR3
on these cells. Sialic acids favor FH binding to the cell surface
via domains 19–20 enabling simultaneous interaction with apoE
via domains 5–7. The effect of sialic acids on FH binding was
demonstrated by neuraminidase treatment of different cell types,
where only monocytes showed a clear reduction in FH binding
at different cell surface sialic acid densities. Moreover, binding
of FH on THP-1 macrophages clearly reduced C3b deposition
on these cells suggesting that FH binding to these cells prior to
C3b deposition has an effect on local complement activation. As
demonstrated by our mRNA expression data, FH expression on
all THP-1 cell types was almost or completely absent, while apoE
expression was clearly increased both by THP-1 macrophages
and cholesterol-loaded cells.
We observed that FH did not induce secretion or expression
of apoE by the studied cells but slightly reduced apoE
concentrations in the culture media. However, FH significantly
increased binding of apoE especially to cholesterol-loaded THP-
1 cells that also showed the highest FH binding. According to
trypan blue staining the increase in FH binding was not due to
cell damage as the cell viabilities were the same in the absence
and presence of FH. It is possible that this kind of rebinding
or apoE capturing on the macrophage surfaces could promote
apoE recycling that has been suggested to reduce intracellular
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FIGURE 6 | Schematic illustrating the putative mechanism of the effect of factor H-apoE interaction in reducing inflammation in atherosclerotic lesions. Binding of
factor H on apoE containing HDL particles reduces plasma complement activation (21) while elevated binding of apoE on monocytes/macrophages/foam cells via FH
might reduce local inflammation and cholesterol efflux.
cholesterol accumulation and thereby prevent formation of foam
cells. Previous studies have shown that apoE can be spared
from degradation in lysosomes and recycled to the cell surface
in order to maximize cholesterol removal from the cell (41).
The intracellular ATP binding cassette transporter ABCA1 is
an important regulator of cellular cholesterol homeostasis. It is
involved in apoE secretion and in lipidating apoE-containing
particles secreted by macrophages. ABCA1 is suggested to
promote apoE recycling as well. Our results on the effect of
FH on cholesterol efflux suggest that the increased binding of
apoE caused by FH could promote apoE recycling and thereby
maximize cholesterol efflux from macrophages. Importantly, the
mRNA expression data showed increase in ABCA1 expression
on FH-treated cholesterol-loaded THP-1 macrophages and a
significant increase in the expression of PPAR-α transcription
factor that is known to induce ABCA1 expression. This clearly
suggests an anti-atherogenic function for FH-apoE interaction
(42).
We found that treatment of THP-1 cells for 24 h clearly altered
transcription of several genes associated with inflammation,
atherosclerosis, and the complement system (Table 2). These
changes occurred mainly within PMA-differentiated THP-1
macrophages and cholesterol loaded THP-1 macrophages while
THP-1 monocytes as well as non-loaded THP-1 macrophages
were less responsive to the treatment. These data did not
suggest any clear M1/M2 polarization but general trend was
that FH reduced significantly transcription of proinflammatory
genes in macrophages (such as CXCR3, CCL5, SAAL1) but
increased transcription of antiatherogenic genes that are involved
in enhanced lipid metabolism (such as ABCA1, PPAR-α)
mainly in cholesterol loaded cells. FH did not only result
in increase in transcription of ABCA1 in cholesterol loaded
macrophages but also in ABCA1 protein expression and PPAR-α
transcription. This indicates that FH may affect in macrophage
cholesterol efflux via this transcription factor known to activate
ABCA1-mediated cholesterol efflux in humanmacrophages (42).
Therefore, the difference between the transcription levels cannot
be explained by the instability of mRNA transcripts that does
not always correlate with the corresponding levels of protein
expression (51).
Certain mutations and polymorphisms of FH are associated
with AP dysregulation mediated diseases such as AMD, DDD,
and aHUS. AMD and DDD are characterized by formation of
deposits in the eye (drusen) or kidney (glomerular basement
membrane) that are rich in complement activation products
and, most importantly, also contain high amounts of apoE (52,
53). Therefore, in addition to atherosclerosis the pathogenesis
of diseases such as AMD and DDD could be related to the
FH and apoE-macrophage interactions. While FH interaction
with apoE launches a concerted action leading to several anti-
inflammatory responses on macrophages (Figure 6) genetic or
acquired disturbances in this homeostatic mechanism could
promote the progression of atherosclerotic and other analogous
lesions.
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